The Biotime 2 in 1 (CEA/AFP) Rapid Quantitative Test is a fluorescence-based immunoassay designed to measure CEA and AFP concentrations in serum or plasma samples within 10 minutes. Both markers are clinically significant for evaluating and diagnosing primary liver cancer, metastatic liver disease, and other malignancies.

AFP (Alpha-fetoprotein) is a major plasma protein produced by the fetal liver and yolk sac during development. Its levels decrease rapidly after birth, remaining low in healthy adults. Elevated AFP may indicate hepatocellular carcinoma, germ cell tumors, or metastatic liver involvement.

CEA (Carcinoembryonic Antigen), a glycoprotein involved in cell adhesion, is normally produced during fetal development but is nearly absent in healthy adults. Elevated CEA levels are associated with colorectal, pancreatic, gastric, and lung cancers, making it an essential biomarker for tumor monitoring and recurrence evaluation.

By combining these two clinically relevant markers, the Biotime 2 in 1 (CEA/AFP) test delivers comprehensive diagnostic value, reducing testing time while maintaining high analytical sensitivity and accuracy.